Company Exicure Inc Other OTC
Equities
US30205M1018
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Immuno-oncology Therapeutics
100.0
%
| 0 | 100.0 % | 29 | 100.0 % | -6,068.12% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 29 | 100.0 % | -6,068.12% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Kang
CEO | Chief Executive Officer | 63 | 23-02-23 |
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 22-11-30 |
Investor Relations Contact | 47 | - | |
Joshua Miller
AUD | Comptroller/Controller/Auditor | 48 | 22-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 22-11-30 |
Paul Kang
CEO | Chief Executive Officer | 63 | 23-02-23 |
Hyuk Joon Ko
BRD | Director/Board Member | - | 23-08-22 |
Dongho Lee
BRD | Director/Board Member | - | 23-08-20 |
Hojoon Lee
BRD | Director/Board Member | - | 23-08-22 |
Minhee Eom
BRD | Director/Board Member | - | 23-09-25 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 8,648,307 | 4,753,248 ( 54.96 %) | 0 | 54.96 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |